There are currently 2644 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center and Brigham and Women's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
NCT05280314
Recruiting
This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indications.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Melanoma, Squamous Cell Carcinoma of Head and Neck
Register for Updates
A Clinical Trial Via Telepsychiatry of Treatments for the Management of Emotional Dysregulation in Youth
NCT03911414
Recruiting
This study consists of a 6-week, open-label, randomized clinical trial study to compare efficacy and tolerability of the natural treatments omega-3 fatty acids, inositol, and N-acetylcysteine (NAC) in the treatment of mood dysregulation in children and adolescents (ages 5-17). Subjects will be randomized to one of two arms: 1) omega-3 fatty acids plus inositol or 2) NAC.
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
03/15/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Mood Disturbance, Mood Disorders, Natural Supplements, Alternative Treatment
Register for Updates
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
NCT05826678
Recruiting
This study aims to understand the use of continuous glucose monitors (CGM) in Asian Americans with type 2 diabetes (T2D). Researchers will compare participants on continuous glucose monitors with participants using fingerstick self-monitoring with the aim of answering the following questions: 1. Check if continuous glucose monitoring is doable and consistent for this group, and see how it affects their quality of life. 2. Estimate how well the health outcomes (glucose and lipid markers) vary ov... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
03/14/2024
Locations: Joslin Diabetes Center, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Cryoablation+Ipilimumab+Nivolumab in Melanoma
NCT05779423
Recruiting
The aim of this study is to find out whether the combination of two approved drugs, ipilimumab and nivolumab, in combination with cryoablation are safe and effective for participants who have an unresectable melanoma that is resistant, or is growing, after receiving immunotherapy with a PD-1 inhibitor. The names of the study interventions involved in this study are: * Cryoablation (an interventional radiology procedure that freezes part of a tumor) * Ipilimumab (an immunotherapy) * Nivolumab (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Metastatic Melanoma, Skin Cancer
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT06322693
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: GSK Investigational Site, Boston, Massachusetts
Conditions: Neoplasms
Register for Updates
Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
NCT06146920
Recruiting
The goal of this prospective study to investigate the use of circulating tumor DNA (ctDNA) to guide end of therapy decisions in patients with melanoma or non-small-cell lung cancer. The main question it aims to answer is: • Do patients with metastatic melanoma or non-small-cell lung cancer, who have received at least 12 months of immune checkpoint inhibition (monotherapy or in combination) with evidence of disease response/control on imaging and have no evidence of circulating tumor DNA, have... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Melanoma, Non-small Cell Lung Cancer
Register for Updates
Eliminating Barriers to Colorectal Cancer Screening Using Rapid Cycle Testing: A Pilot Study
NCT05524428
Recruiting
The investigators will use a mixed methods study i.e. focus groups involving CHC staff as well as quantitative study which involves analyzing data that is available from the EHR and DRVS population management platform.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Codman Square Health Center, Boston, Massachusetts
Conditions: Colo-rectal Cancer
Register for Updates
A Single Session Parenting Intervention for Children on a Outpatient Therapy Waitlist
NCT06043271
Recruiting
Cognitive Behavioral Therapy (CBT) is the treatment of choice for youth anxiety. However, up to 80% of youth with anxiety disorders do not access the services they need. Child CBT clinics nationwide have extremely long waits, on the order of 10-12 months. This leads to a vicious cycle, as children waiting for care experience worsening symptoms and decreased motivation, so that by the time they access care, their needs are more intensive and the treatment lasts longer and it takes longer for new... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Anxiety Disorders
Register for Updates
AZD6738 for Patients With Progressive MDS or CMML
NCT03770429
Recruiting
This research study is studying a research drug called AZD6738 as a possible treatment for Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia .
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: BIDMC, Boston, Massachusetts +2 locations
Conditions: Leukemia, Myelodysplastic Syndrome
Register for Updates
Cisplatin+Pembrolizumab+RT in Vulvar Cancer
NCT04430699
Recruiting
This research is being done to see how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma. This research study involves the following: * Cisplatin (standard of care drug) * Pembrolizumab (investigational drug) * Radiation Therapy (standard of care intervention)
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Vulvar Cancer, Vulvar Squamous Cell Carcinoma
Register for Updates
CARv3-TEAM-E T Cells in Glioblastoma
NCT05660369
Recruiting
The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma. The name of the treatment intervention used in this research study is: -CARv3-TEAM-E T Cells (or Autologous T lymphocytes).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
Register for Updates
Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
NCT04902833
Recruiting
This cross-sectional prevalence assessment study involves a single blood draw in specific patient populations to assess for enzymatic and genomic evidence for acquired pyruvate kinase deficiency.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anemia, Hereditary Hemolytic Anemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Clonal Myeloid Neoplasm, Myeloproliferative Neoplasm, Acute Myeloid Leukemia, Clonal Cytopenia of Undetermined Significance, Other Clonal Myeloid Neoplasm, Unexplained Coombs-negative Non-immune Hemolytic Anemia
Register for Updates